Last updated on January 2020

A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib


Brief description of study

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).

Clinical Study Identifier: NCT03673501

Find a site near you

Start Over

Ashford Cancer Centre Research

Kurralta Park, Australia
5.08miles
  Connect »